Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

pembrolizumab 130Carboplatin 106Paclitaxel 65Cisplatin 61Gemcitabine 59Pemetrexed 57Bevacizumab 54Docetaxel 49Fluorouracil 43Oxaliplatin 41atezolizumab 37Dexamethasone 36Leucovorin 34Cetuximab 33130-nm albumin-bound paclitaxel 33Nivolumab 30Cyclophosphamide 30Prednisone 29Rituximab 28Capecitabine 28durvalumab 27Fulvestrant 24Lenalidomide 22enzalutamide 21Letrozole 21Irinotecan 21venetoclax 20Doxorubicin 19ribociclib 18pomalidomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × sotorasib × 30 days × Clear all
NCT05920356 2026-06-04

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen

Phase 3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06333951 2026-05-28

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Amgen

Phase 1 Active not recruiting
49 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡